Fig. 3: Oncoprint representing distribution of oncogenic and variants of uncertain significance (VUS) from archival tumour tissue.
Cohort 1 with niraparib monotherapy (n = 21). Cohort 2 with niraparib and dostarlimab (n = 22).
Fig. 3: Oncoprint representing distribution of oncogenic and variants of uncertain significance (VUS) from archival tumour tissue. | Nature Communications
